Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system

Cardiovascular Research

Volumn 63, Issue 3, 2004, Pages 443-449

  Luchner, A ^a   Schunkert, H ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Alpha receptor; ANP; Beta receptor; Cross talk; Heart failure; Interactions; Natriuretic peptides; Sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NATRIURETIC FACTOR; PROPRANOLOL;

ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SYMPATHETIC TONE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BAROREFLEX; CARDIOMYOPATHY, DILATED; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY; LUNG; MYOCARDIUM; RECEPTORS, ADRENERGIC; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SYMPATHETIC NERVOUS SYSTEM;

EID: 3242768387     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.05.004     Document Type: Review

References (48)

1. Braunwald E., Harrison D., Chidsey C. The heart as an endocrine organ. Am. J. Med. 36:1964;1-4
2. De Bold A.J., Borenstein H.B., Veress A.T., et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28:1981;89-94
3. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human natriuretic polypeptide (alpha-hANP). Biochem. Biophys. Res. Commun. 168:1984;863-870
4. Ardati A., Nemer M. A nuclear pathway for alpha 1-adrenergic receptor signaling in cardiac cells. EMBO J. 12:1993;5131-5139
5. King K.L., Winer J., Phillips D.M., et al. Phenylephrine, endothelin, prostaglandin F2alpha′ and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. Endocrine. 9:1998;45-55
6. Yue T.L., Gu J.L., Wang C., et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J. Biol. Chem. 275:2000;37895-37901
7. Glennon P.E., Kaddoura S., Sale E.M., et al. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ. Res. 78:1996;954-961
8. Hayashi J., Ohni M., Manabe H., et al. Biochemical mechanism of release of atrial natriuretic polypeptide. Jpn. Circ. J. 52:1988;1421-1424
9. Matsubara H., Hirata Y., Yoshimi H., et al. Role of calcium and protein kinase C in ANP secretion by cultured rat cardiocytes. Am. J. Physiol. 255:1988;H405-H409
10. Shields P.P., Glembotski C.C. Regulation of atrial natriuretic factor-(99-126) secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C. J. Biol. Chem. 264:1989;9322-9328
11. Knowlton K.U., Michel M.C., Itani M., et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268:1993;15374-15380
12. Autelitano D., Woodcock E. Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. J. Mol. Cell. Cardiol. 30:1998;1515-1523
13. Schiebinger R.J. Calcium, its role in isoproterenol-stimulated atrial natriuretic peptide secretion by superfused rat atria. Circ. Res. 65:1989;600-606
14. Cui X., Wen J.F., Jin J.Y., et al. Protein kinase-dependent and Ca(2+)-independent cAMP inhibition of ANP release in beating rabbit atria. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282:2002;R1477-R1489
15. Agnoletti G., Rodella A., Cornacchiari A., et al. Isoproterenol induces release of atrial natriuretic peptide from rat atrium in vitro. Am. J. Physiol. 262:1992;H285-H292
16. Ambler S.K., Leite M.F. Regulation of atrial natriuretic peptide secretion by alpha 1-adrenergic receptors: the role of different second messenger pathways. J. Mol. Cell. Cardiol. 26:1994;391-402
17. Hanford D.S., Thuerauf D.J., Murray S.F., et al. Brain natriuretic peptide is induced by alpha 1-adrenergic agonists as a primary response gene in cultured rat cardiac myocytes. J. Biol. Chem. 269:1994;26227-26233
18. Hanford D.S., Glembotski C.C. Stabilization of the B-type natriuretic peptide mRNA in cardiac myocytes by alpha-adrenergic receptor activation: potential roles for protein kinase C and mitogen-activated protein kinase. Mol. Endocrinol. 10:1996;1719-1727
19. Nakagawa O., Itoh H., Harada M., et al. Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by alpha1-adrenergic stimulation. Clin. Exp. Pharmacol. Physiol. Suppl. 22:1995;S183-S185
20. Sei C.A., Glembotski C.C. Calcium dependence of phenylephrine-, endothelin-, and potassium chloride-stimulated atrial natriuretic factor secretion from long term primary neonatal rat atrial cardiocytes. J. Biol. Chem. 265:1990;7166-7172
21. Sei C.A., Irons C.E., Sprenkle A.B., et al. The alpha-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways. J. Biol. Chem. 266:1991;15910-15916
22. Schiebinger R.J., Parr H.G., Cragoe E.J. Calcium: its role in alpha 1-adrenergic stimulation of atrial natriuretic peptide secretion. Endocrinology. 130:1992;1017-1023
23. Barron A., Finn S., Fuller S. Chronic activation of extracellular-signal- regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes. Biochem. J. 371:2003;71-79
24. Ueyama T., Kawashima S., Sakoda T., et al. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J. Mol. Cell. Cardiol. 32:2000;947-960
25. Vara D., Bicknell K.A., Coxon C.H., et al. Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy. J. Biol. Chem. 278:2003;21388-21394
26. Horio T., Nishikimi T., Yoshihara F., et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 35:2000;19-24
27. Kishimoto I., Yoshimasa T., Suga S., et al. Natriuretic peptide clearance receptor is transcriptionally down-regulated by beta 2-adrenergic stimulation in vascular smooth muscle cells. J. Biol. Chem. 269:1994;28300-28308
28. 2+ infusion, and aortic constriction in pigs. Circ. Res. 68:1991;638-644
29. Currie M.G., Newman W.H. Evidence for alpha-1 adrenergic receptor regulation of atriopeptin release from the isolated rat heart. Biochem. Biophys. Res. Commun. 137:1986;94-100
30. Ferrari A.U., Daffonchio A., Cavallazzi A., et al. Effect of atrial natriuretic factor on arterial baroreceptor control of heart rate and blood pressure in conscious rats. J. Hypertens. Suppl. 6:1988;S284-S286
31. Jin H., Yang R.H., Calhoun D.A., et al. Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat. Hypertension. 20:1992;374-379
32. Zhu S.T., Chen Y.F., Wyss J.M., et al. Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. Hypertension. 27:1996;297-302
33. Antunes Rodrigues J., Marubayashi U., Favaretto A.L., et al. Essential role of hypothalamic muscarinic and alpha-adrenergic receptors in atrial natriuretic peptide release induced by blood volume expansion. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10240-10244
34. Hansson M. Natriuretic peptides in relation to the cardiac innervation and conduction system. Microsc. Res. Tech. 58:2002;378-386
35. Davila D.F., Donis J.H., Bellabarba G., et al. Cardiac afferents and neurohormonal activation in congestive heart failure. Med. Hypotheses. 54:2000;242-253
36. Ebert T.J., Skelton M.M., Cowley A.W. Dynamic cardiovascular responses to infusions of atrial natriuretic factor in humans. Hypertension. 11:1988;537-544
37. Ebert T.J. Reflex activation of sympathetic nervous system by ANF in humans. Am. J. Physiol. 255:1988;H685-H689
38. Ebert T.J., Cowley A.W. Atrial natriuretic factor attenuates carotid baroreflex-mediated cardioacceleration in humans. Am. J. Physiol. 254:1988;R590-R594
39. Butler G.C., Senn B.L., Floras J.S. Influence of atrial natriuretic factor on heart rate variability in normal men. Am. J. Physiol. 267:1994;H500-H505
40. Brunner La Rocca H.P., Kaye D.M., Woods R.L., et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. 37:2001;1221-1227
41. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. 4:1998;37-44
42. Hama J., Nagata S., Takenaka T., et al. Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. Angiology. 46:1995;511-516
43. Nakaoka H., Kitahara Y., Amano M., et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 10:1987;221-225
44. Luchner A., Burnett J.C., Jougasaki M., et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J. Am. Coll. Cardiol. 32:1998;1839-1844
45. Harkness A., McDonagh T., Lawrence A., et al. Cardiac medication and brain natriuretic peptide. Eur. Heart J. 19:1998;447. [abstract]
46. Yoshimoto T., Naruse M., Irie K., et al. Beta-adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides. Eur. J. Pharmacol. 351:1998;61-66
47. Yoshimoto T., Naruse M., Tanabe A., et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 139:1998;81-88
48. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 106:2002;2454-2458